Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Infectious Disease

Articles with lock require a GLG News subscription
Posted January 14, 2008
Universal flu vaccine shows early promise
Analysis of: Universal flu vaccine shows early promise | www.fiercebioresearcher.com
Author: GLG Member Program Contributor
Targeting a part of the influenza virus which does not mutate or a regular basis is a great idea. If the clinical data supports its efficacy, it would, indeed, be a novel approach to influenza vaccination.
Posted January 14, 2008
Universal flu vaccine shows early promise
Analysis of: Universal flu vaccine shows early promise | www.fiercebioresearcher.com
Author: GLG Member Program Contributor
If early results are confirmed, this vaccine will revolutionize influenza immunization          
Posted January 14, 2008
Universal flu vaccine shows early promise
Analysis of: Universal flu vaccine shows early promise | www.fiercebioresearcher.com
Author: GLG Member Program Contributor
A vaccine that combats all forms of flu-WOW. Let us see further results first.
Posted January 14, 2008
Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
Analysis of: Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C | www.hivandhepatitis.com
Author: GLG Member Program Contributor
In this small pilot study, R7128 at 1500 mg twice daily combined with Pegasys + ribavirin led to a rapid viral response (HVC RNA <15 IU/mL at week 4) in 85% of patients compared with  35% at 500 mg twice daily and 10% with Pegasys + ribavirin alone.  R7128 did not add much toxicity...
Posted January 9, 2008
Ouch! Cervical cancer shots painful
Analysis of:  Ouch! Cervical cancer shots painful | news.yahoo.com
Author: GLG Member Program Contributor
If you read the CDC analysis of January 2007, you would conclude that both the Merck and GSK vaccines offer little advantage to females under 30 years of age. Why the enormous campaign then by the marketers of these vaccines to get them in use? Since they only cover 70% of the high risk strains anyway,...
Posted January 9, 2008
Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Analysis of: Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 | www.pipelinereview.com
Author: GLG Member Program Contributor
This drug which clearly focuses on antibiotic resistant strains  will be a welcome addition if it does not have significant side effects.
Posted January 8, 2008
Ouch! Cervical cancer shots painful
Analysis of:  Ouch! Cervical cancer shots painful | news.yahoo.com
Author: GLG Member Program Contributor
Ever had a sore arm for two days following a tetanus vaccine?
Posted January 8, 2008
Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Analysis of: Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741 | www.pipelinereview.com
Author: GLG Member Program Contributor
Successful completion of these studies in community acquired pneumonia and skin and soft tissue infection will hopefully lead to approval of an additional new drug active against drug resistant bacteria, such as MRSA.
Posted January 8, 2008
Ouch! Cervical cancer shots painful
Analysis of:  Ouch! Cervical cancer shots painful | news.yahoo.com
Author: GLG Member Program Contributor
The benefit/risk  ratio is so positive that this should be NO excuse not to use the vaccine.
Posted January 3, 2008
Ventilator-associated pneumonia - the wrong quality measure for benchmarking
Analysis of: Ventilator-associated pneumonia - the wrong quality measure for benchmarking | www.annals.org
Author: GLG Member Program Contributor
Hospitals and physicians are under increasing pressure to follow benchmarks or be penalized. When this happens and when already lean payments are cut further, how can that lead to an increase in quality?
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 210

GLG News: What Experts Think Is Important





Analytics